The combination drug ¡®Duodart¡¯ that contains ¡®dutasteride¡¯ and ¡®tamsulosin¡¯ may be prescribed in general hospitals in Korea.

According to industry sources, Duodart, GSK Korea¡¯s fixed-dose combination drug for benign prostatic hyperplasia (BPH), has recently passed the drug committee (DC) review of Sinchon Severance Hospital and is undergoing landing procedures at major medical institutions across the country.

The drug was granted insurance benefits starting in March this year. Duodart is reimbursed for ™“ patients with ¡®benign prostatic hyperplasia (BPH)¡¯ who satisfy both of the following conditions: International Prostate Symptom Score (IPSS) of 8 or higher and ¡ã Ultrasonogra